Project Grant R01CA304291
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $499K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- The National Cancer Institute awarded The University of Kentucky Research Foundation $390,453 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate systemic crosstalk between tumor cells and neutrophils in triple-negative breast cancer. The project examines how triple-negative breast cancer tumors induce production of pro-tumor neutrophils and develops targeted strategies to selectively inhibit these subsets. The research focuses on tumor-derived granulocyte...
- The National Institutes of Health National Cancer Institute awarded Duke University $690,011 on July 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate HER2 isoform signaling in breast cancer metastasis and immune escape. The research examines how distinct HER2 protein isoforms—including the exon 16 null isoform and the N-terminally truncated P95 isoform—drive different tumor cell behaviors associated with early invasion and treatment resistance. Preliminary data in...
- The National Institutes of Health National Cancer Institute awarded Vanderbilt University Medical Center $695,884 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate selective loss of HLA gene products in triple-negative breast cancer immunobiology. The research examines how tumor cells evade immune checkpoint inhibition through downregulation or deletion of MHC-I (major histocompatibility complex I) expression. Preliminary data from the recipient's...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $637,509 to the University of California, San Diego on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396, R01CA305983) to investigate GIV (GA-interacting vesicle-associated protein) as a master regulator of cancer cell signaling autonomy. The research examines how cancer cells sustain growth in nutrient- and growth factor-limited environments through...
- The National Cancer Institute of the Department of Health and Human Services awarded the Beckman Research Institute of the City of Hope $733,864 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and characterize stimulatory immune checkpoints regulating macrophage-mediated programmed cell removal in tumor immunosurveillance. The research uses high-throughput CRISPR-based screening to investigate how a novel stimulatory innate immune checkpoint interacts with...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $394,214 to the University of North Carolina at Chapel Hill on May 19, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds development of a transgenic mouse model and novel cell culture reagents for Epstein-Barr virus-driven solid tumors, including nasopharyngeal carcinoma and gastric cancer. The proposed transgenic mice will be fully...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...